WebMar 6, 2015 · The safety and efficacy of filgrastim products given simultaneously with cytotoxic chemotherapy have not been established. Do not use Zarxio in the period 24 hours before through 24 hours after the administration of cytotoxic chemotherapy. Web- Burkitt lymphoma participants must have had at least 1 prior cytotoxic chemotherapy- containing regimen that also contained an anti-CD20 monoclonal antibody. ... - Absolute neutrophil count greater than or equal to 1000/mm^3 without the support of filgrastim or other growth factors
Neupogen, Granix, Zarxio, Nivestym (filgrastim, tbo …
WebEflapegrastim (Rolontis ® ) is a novel, long-acting hematopoietic growth factor consisting of a recombinant human granulocyte-colony stimulating factor (rhG-CSF) analog conjugated … WebFilgrastim (recombinant human granulocyte colony stimulating factor, rG-CSF) is a hematopoietic growth factor which regulates the production and function of neutrophils. … barin group idaho
Dosing, Administration, and Storage GRANIX® (tbo-filgrastim) …
WebDec 31, 1994 · Background: The aim of the study was to evaluate the role and potential benefit of granulocyte colony-stimulating factor (G-CSF, Filgrastim), administered following cytotoxic chemotherapy with the ABVD regimen in Hodgkin's disease, in maintaining cycle schedule and dose intensity and in decreasing neutropenia and number of infections. ... WebThe recommended starting dose of filgrastim is 1.0 MU/kg/day (10 μg/kg/day). The first dose of filgrastim should be administered at least 24 hours following cytotoxic … WebThe Filgrastim-Group and the No-CSF-Group had a 32% (1.10-1.56, P = 0.002) and 8% (1.04-1.12, P < 0.001) increased risk of incidence of neutropenia, respectively, compared with the Pegfilgrastim-Less-Than-14-Days-Group. The risk of incidence of neutropenia was the same with the Pegfilgrastim-More-Than-14-Days-Group and Pegfilgrastim-Less-Than ... baring road se12